AstraZeneca aims to be a leader in neuroscience research delivering a range of life-changing medicines in key areas of unmet medical need. We are making great research efforts in diseases related to the central nervous system (CNS).
Our research in this field is focused on neurological diseases, psychiatric disorders, and pain and anaesthesia.
Key areas of partnering interest
Psychiatry
Schizophrenia
- Novel therapeutics targeting psychosis with clinical proof of concept
- Novel therapeutics targeting cognition
- 3rd generation anti-psychotic
Depression/anxiety
- MT-1/2 agonist (phase II/III)
- Triple re-uptake inhibitor (serotonin / norepinephrine / dopamine)
- 1st generation CRF-1 antagonist (phase II/III)
- Novel diagnostic tools
- Novel biomarkers and genetic markers
- Novel ligands for in-vivo occupancy and PET imaging
Neurology
- Symptomatic treatment agents superior to AChE inhibitors
- Decrease of amyloid beta - small molecules approach
- Inhibitors of tau phosphorylation
Analgesia
Novel therapeutics for chronic pain (both neuropathic and
nociceptive) with particular interest in:
- Peripheral ion channels modulators:
- Novel channel targets and platform technologies
- VR1 antagonists
- Sodium channel (NaV 1.7, 1.8) blockers
- Calcium channel modulation
- Potassium channel modulation
- Monoamine modulators
- CCR2 antagonists
- Bradykinin receptor (B1) antagonists
- mPGES inhibitors
- Novel diagnostic clinical tools
- Novel biomarkers and genetic biomarkers
- Therapies with clinical proof of concept
Contacts
jit.patel@astrazeneca.com
Psychiatry pre-clinical and technology. Analgesia
Hans.Hultberg@astrazeneca.com
Neurology
jeff.witcher@astrazeneca.com
Analgesia clinical/later stage
mark.odorisio@astrazeneca.com
Psychiatry clinical/later stage
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
